WO2002042423A3 - Modulation antisens de l'expression de src-2 - Google Patents

Modulation antisens de l'expression de src-2 Download PDF

Info

Publication number
WO2002042423A3
WO2002042423A3 PCT/US2001/044220 US0144220W WO0242423A3 WO 2002042423 A3 WO2002042423 A3 WO 2002042423A3 US 0144220 W US0144220 W US 0144220W WO 0242423 A3 WO0242423 A3 WO 0242423A3
Authority
WO
WIPO (PCT)
Prior art keywords
src
expression
antisense modulation
methods
compounds
Prior art date
Application number
PCT/US2001/044220
Other languages
English (en)
Other versions
WO2002042423A2 (fr
Inventor
Burt W O'malley
Frank C Bennett
Lex M Cowsert
Original Assignee
Isis Pharmaceuticals Inc
Baylor College Medicine
Burt W O'malley
Frank C Bennett
Lex M Cowsert
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Isis Pharmaceuticals Inc, Baylor College Medicine, Burt W O'malley, Frank C Bennett, Lex M Cowsert filed Critical Isis Pharmaceuticals Inc
Priority to AU2002237678A priority Critical patent/AU2002237678A1/en
Priority to JP2002545129A priority patent/JP2004536558A/ja
Priority to EP01986485A priority patent/EP1343913A2/fr
Publication of WO2002042423A2 publication Critical patent/WO2002042423A2/fr
Publication of WO2002042423A3 publication Critical patent/WO2002042423A3/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/31Chemical structure of the backbone
    • C12N2310/315Phosphorothioates
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/32Chemical structure of the sugar
    • C12N2310/3212'-O-R Modification
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/33Chemical structure of the base
    • C12N2310/334Modified C
    • C12N2310/33415-Methylcytosine
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/34Spatial arrangement of the modifications
    • C12N2310/341Gapmers, i.e. of the type ===---===
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/34Spatial arrangement of the modifications
    • C12N2310/346Spatial arrangement of the modifications having a combination of backbone and sugar modifications
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/582Recycling of unreacted starting or intermediate materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Composés antisens, compositions et procédés servant à moduler l'expression de SRC-2. Ces compositions contiennent des composés antisens, en particulier, des oligonucléotides antisens, ciblés vers des acides nucléiques codant SRC-2. Procédés d'utilisation de ces composés afin de moduler l'expression de SRC-2 et de traiter des maladies associées à l'expression de SRC-2.
PCT/US2001/044220 2000-11-27 2001-11-26 Modulation antisens de l'expression de src-2 WO2002042423A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU2002237678A AU2002237678A1 (en) 2000-11-27 2001-11-26 Antisense modulation of src-2 expression
JP2002545129A JP2004536558A (ja) 2000-11-27 2001-11-26 Src−2発現のアンチセンスモジュレーション
EP01986485A EP1343913A2 (fr) 2000-11-27 2001-11-26 Modulation antisens de l'expression de src-2

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US72353000A 2000-11-27 2000-11-27
US09/723,530 2000-11-27

Publications (2)

Publication Number Publication Date
WO2002042423A2 WO2002042423A2 (fr) 2002-05-30
WO2002042423A3 true WO2002042423A3 (fr) 2003-01-30

Family

ID=24906651

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/044220 WO2002042423A2 (fr) 2000-11-27 2001-11-26 Modulation antisens de l'expression de src-2

Country Status (4)

Country Link
EP (1) EP1343913A2 (fr)
JP (1) JP2004536558A (fr)
AU (1) AU2002237678A1 (fr)
WO (1) WO2002042423A2 (fr)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998056806A1 (fr) * 1997-06-12 1998-12-17 The Regents Of The University Of California Proteine de coactivation de facteur de transcription, p/cip

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998056806A1 (fr) * 1997-06-12 1998-12-17 The Regents Of The University Of California Proteine de coactivation de facteur de transcription, p/cip

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GEWIRTZ ET AL.: "Facilitating oligonucleotide delivery: helping antisense deliver on its promise", PROC. NATL. ACAD. SCI. USA, vol. 93, April 1996 (1996-04-01), pages 3161 - 3163, XP002909913 *
VOEGEL ET AL.: "TIF2, a 160 kDa transcriptional mediator for the ligand-dependent activation function AF-2 of nuclear receptors", EMBO J., vol. 15, no. 14, 1996, pages 3667 - 3675, XP002045757 *

Also Published As

Publication number Publication date
AU2002237678A1 (en) 2002-06-03
EP1343913A2 (fr) 2003-09-17
JP2004536558A (ja) 2004-12-09
WO2002042423A2 (fr) 2002-05-30

Similar Documents

Publication Publication Date Title
WO2002036743A3 (fr) Modulation antisens de l'expression de calreticuline
WO2002092772A3 (fr) Modulation antisens de l'expression de ptp1b
AU2001290706A1 (en) Antisense modulation of clusterin expression
EP1248794A4 (fr) Modulation antisens de l'expression de la proteine smad7
WO2003011887A3 (fr) Modulation antisens de l'expression de l'apolipoproteine b
WO2002010378A3 (fr) Modulation antisens de l'expression de ptp1b
WO2003046132A3 (fr) Modulation antisens de l'expression du myd88
EP1131332A4 (fr) Modulation antisens de l'expression de la kappa b kinase beta inhibitrice
EP1131107A4 (fr) Modulation antisens de l'expression de kappa b kinase alpha inhibitrice
WO2001029175A3 (fr) Modulation antisens de l'expression de fra-1
WO2003053341A3 (fr) Modulation antisens de l'expression de ship-1
WO2002095053A3 (fr) Modulation antisens de l'expression des src-c
WO2001083513A3 (fr) Modulation antisens de l'inhibiteur de l'expression de la fixation 1 a l'adn
WO2002050248A3 (fr) Modulation antisens de l'expression de l'hepsine
WO2003052062A3 (fr) Modulation antisens de l'expression de cd36l1
WO2002036810A3 (fr) Modulation antisens de l'expression de la taline
EP1165145A4 (fr) Regulation antisens d'expression de mdmx
EP1235924A4 (fr) Modulation antisens de l'expression de l'activateur du recepteur de facteur kappa b nucleaire (rank)
WO2003027229A3 (fr) Modulation antisens de l'expression de rip2
WO2003044167A3 (fr) Modulation antisens destinee a l'expression d'un recepteur fxr humain
WO2000061786A3 (fr) Modulation antisens de l'expression de pdk-1
WO2002041836A3 (fr) Modulation antisens de l'expression de src-1
WO2003031576A3 (fr) Modulation antisens de l'expression de l'inhibiteur kappa b kinase-gamma
WO2002055535A3 (fr) Modulation antisens de l'expression de la cytohesine-1
WO2002042425A3 (fr) Modulation antisens de l'expression mp-1

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2002545129

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2001986485

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001986485

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2001986485

Country of ref document: EP